RxDoctor Payments Data

Michael Higginbotham, MD

Family Medicine · Rockport, ARNPI 1619992377

Payments from drug & device makers

$1,934in general payments, 2019–2025

Across 146 payments — averaging $13.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Pfizer$304
  • Novo Nordisk$248
  • GSK$178
  • AbbVie$164
  • Merck$127
  • plus $516 from 15 others

What the payments were for

  • Food & beverage$1,92299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,934 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$606,616
Medicare patients
731
Services billed
14,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$177,673
OzempicSemaglutide135$133,476
JardianceEmpagliflozin131$119,477
OtezlaApremilast12$77,787
MounjaroTirzepatide42$52,393
FarxigaDapagliflozin Propanediol42$43,035
EntrestoSacubitril/Valsartan32$38,016
LinzessLinaclotide36$34,351
TrulicityDulaglutide18$33,816
Combivent RespimatIpratropium/Albuterol Sulfate29$26,362
XareltoRivaroxaban23$24,927
Soliqua 100-33Insulin Glargine/Lixisenatide25$24,043
JanuviaSitagliptin Phosphate25$23,523
ViberziEluxadoline12$18,163
Breo ElliptaFluticasone/Vilanterol29$15,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$304$177,673212 claims
Novo NordiskOzempic$248$133,476135 claims
Lilly USA, LLCMounjaro, Trulicity$15$86,20960 claims
AmgenOtezla$105$77,78712 claims
AbbVieLinzess, Viberzi, Synthroid, Combigan$164$57,705104 claims
AstraZenecaFarxiga, Symbicort, Brilinta$398$55,03367 claims
NovartisEntresto$38$38,01632 claims
GSKBreo Ellipta, Anoro Ellipta$178$27,17240 claims
Johnson & JohnsonXarelto$95$24,92723 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$26$24,04325 claims
MerckJanuvia$127$23,52325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Rockport

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →